The converging roles of sequestosome-1/p62 in the molecular pathways of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Neurobiol Dis

Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, 2 Technology Place, NSW 2109, Australia.. Electronic address:

Published: May 2022

Investigations into the pathogenetic mechanisms underlying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have provided significant insight into the disease. At the cellular level, ALS and FTD are classified as proteinopathies, which is motor neuron degeneration and death characterized by pathological protein aggregates or dysregulated proteostasis. At both the clinical and molecular level there are common signaling pathways dysregulated across the ALS and FTD spectrum (ALS/FTD). Sequestosome-1/p62 is a multifunctional scaffold protein with roles in several signaling pathways including proteostasis, protein degradation via the ubiquitin proteasome system and autophagy, the antioxidant response, inflammatory response, and apoptosis. Notably these pathways are dysregulated in ALS and FTD. Mutations in the functional domains of p62 provide links to the pathogenetic mechanisms of p62 and dyshomeostasis of p62 levels is noted in several types of ALS and FTD. We present here that the dysregulated ALS and FTD signaling pathways are linked, with p62 converging the molecular mechanisms. This review summarizes the current literature on the complex role of p62 in the pathogenesis across the ALS/FTD spectrum. The focus is on the underlying convergent molecular mechanisms of ALS and FTD-associated proteins and pathways that dysregulate p62 levels or are dysregulated by p62, with emphasis on how p62 is implicated across the ALS/FTD spectrum.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2022.105653DOI Listing

Publication Analysis

Top Keywords

als ftd
20
signaling pathways
12
dysregulated als
12
amyotrophic lateral
8
lateral sclerosis
8
als
8
sclerosis als
8
als frontotemporal
8
frontotemporal dementia
8
dementia ftd
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Xiangya Hospital, Central South University, Changsha, Hunan, China.

Background: Frontotemporal dementia (FTD) exhibits clinical phenotypic and genetic heterogeneity. However, reports on the clinical phenotypic characteristics and the frequency of genetic mutations in large-sample Chinese populations with FTD are lacking. Furthermore, the FTD diagnostic performance of plasma neurodegenerative biomarkers remains unclear.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

UK Dementia Research Institute at University College London, London, United Kingdom; Dementia Research Centre at University College London, London, United Kingdom.

Transactive response DNA-binding protein 43 (TDP-43) has emerged as a pivotal player in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and the recently described limbic-predominant age-related TDP-43 encephalopathy (LATE). Detecting TDP-43 pathology in a minimally invasive manner is crucial for early diagnosis, monitoring disease progression and the assessment of therapeutic interventions. This talk explores recent advancements in the discovery and validation of novel biofluid measures aimed at detecting and characterising TDP-43 pathology.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

AC Immune, Lausanne, Vaud, Switzerland.

Background: Aggregated TDP-43 is found as the main component of pathological inclusions in amyotrophic lateral sclerosis (ALS), limbic-predominant age-related TDP-43 encephalopathy (LATE), in 50% of patients with frontotemporal dementia (FTD), and is present as co-pathology in other neurodegenerative diseases, including Alzheimer's disease (AD). Biofluid or imaging biomarkers of TDP-43 pathology are currently unavailable. Direct detection of TDP-43 aggregates holds promise for unraveling the pathobiology of disease and for enabling precision medicine approach via improved diagnosis, patient stratification and assessment of therapeutic efficacy in clinical trials in AD and related diseases.

View Article and Find Full Text PDF

Background: The quantification of neurofilament light chain (NfL) in blood and cerebrospinal fluid (CSF) has proved useful in many contexts, for the diagnosis and prognosis of various neurological disorders. There is, however, a diversity of practices between centers, essentially linked to the context of use (COU), analytical methods, consideration of comorbidities, determination of cut-points or use of interpretation scales. Finally, for the same biochemical profile, the interpretation and reporting of results may differ from one center to another, raising the question of test commutability.

View Article and Find Full Text PDF

Background: Comorbid cognitive impairment in amyotrophic lateral sclerosis (i.e., ALS-FTD), is associated with adverse clinical outcomes and survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!